Dr Madhav P. Ghimire and the crystallography of drug molecules

Dr Madhav P. Ghimire is a Nepali chemist whose work sits at the meeting point of physical chemistry, medicinal chemistry and pharmaceutical analysis. His focus, the crystallography of drug molecules, asks a practical question: what does a medicine look like when its atoms settle into an ordered solid? Single-crystal X-ray diffraction can answer with striking precision, revealing molecular shape, hydrogen-bond networks and crystal packing that a conventional structural formula hides.

Those details can influence how a medicine dissolves, survives storage and reaches its target. Ghimire’s profile matters to students and researchers because it links laboratory instrumentation with decisions made during drug design and manufacturing, while showing how a scientist from Nepal participates in international chemistry research.

A Nepali scientific pathway

Ghimire’s career connects Nepal’s chemical education community with an international specialism in molecular structure. His crystallographic work asks physical questions about organic and medicinal compounds: How are the atoms arranged? Which intermolecular forces stabilise the lattice? Can those features help explain stability, handling or therapeutic performance?

The method demands patience and interpretive skill. A diffraction experiment produces spots and intensities, but converting them into a credible chemical structure requires attention to symmetry, data quality, disorder and chemical plausibility. For Ghimire, crystallography is therefore more than taking photographs of crystals; it is a rigorous way of connecting a three-dimensional structure with real molecular behaviour.

Reading a medicine in three dimensions

A drug can exist as more than one crystal form. These polymorphs contain the same molecule, yet different arrangements may alter dissolution rate, hygroscopicity, stability or tabletability. A rare polymorph can even transform into a more stable form during heating or milling. Single-crystal diffraction distinguishes these structures, while energetic stability and manufacturing behaviour turn a structural observation into a pharmaceutical concern.

The active pharmaceutical ingredient is not usually handled as an isolated crystal during development. It is blended with excipients, compressed, coated and stored, sometimes for long periods. Knowledge of crystal form therefore supports formulation decisions and manufacturing controls, including quality-by-design programmes that aim to understand which material properties matter rather than merely reproduce a batch. It also informs intellectual-property decisions when a novel crystal form demonstrates a distinct and patentable product characteristic.

Australia provides a demanding local context for this work. The Therapeutic Goods Administration evaluates medicines seeking inclusion in the Australian Register of Therapeutic Goods under the Therapeutic Goods Act 1985. Sponsors must provide evidence covering quality, safety and efficacy, and a medicine’s physical form can become part of that evidence when it affects consistency or performance. Generic and brand-name products, including widely used products such as paracetamol, share crowded pharmacy shelves, making reliable solid-state characterisation valuable across the market.

From structure to pharmaceutical performance

A crystal structure is one part of a broader analytical picture. Ghimire’s expertise is most useful when single-crystal X-ray diffraction is combined with powder diffraction, thermal analysis, spectroscopy and measurements of solubility or dissolution. Each method sees a different aspect of the same material: atomic arrangement, heat response, chemical environment and behaviour in liquid. Agreement between them strengthens a conclusion; disagreement can expose polymorphism, disorder or a processing problem.

For medicinal chemists, this knowledge supports rational drug design. A crystal may reveal whether hydrogen-bond donors and acceptors can form a stable lattice, how flexible a molecule is in its solid state, and whether a conformation differs from the biologically active geometry suggested by solution studies and molecular docking. Such information can guide analogue selection and salt or co-crystal screening. It cannot establish binding or efficacy by itself, but it can prevent a promising structure from being pursued on an incomplete understanding of its physical chemistry.

In Melbourne and Sydney, this chain runs from the laboratory bench to the community pharmacy. It includes formulation scientists characterising an ingredient, clinical teams examining a candidate, and pharmacists dispensing repeat prescriptions to patients who may take the same medicine for years. Australia’s clinical trial system adds Clinical Trial Notification and Clinical Trial Application pathways, which distinguish trial risk and oversight while state and territory ethics requirements remain central. Solid-state evidence helps ensure that the material described during development is the material represented in later batches and trials.

Collaboration, mentorship and public value

Ghimire’s profile also illustrates the value of connecting specialist research with a wider chemistry community. NepaChem can make crystallography legible to students who may never have handled a diffractometer, while preserving the context of a Nepali scientist’s career. Clear explanations of diffraction data, molecular packing and polymorphs support laboratory learning, professional development and informed conversations about medicines.

The same principle crosses scientific boundaries. For readers interested in how specialist communities share knowledge beyond formal papers, this public astronomy resource provides an example of accessible public engagement with a technical subject. Astronomy and crystallography use different instruments and questions, yet both succeed when complex evidence is presented in a form that invites curiosity rather than intimidating newcomers.

The next crystallographic contribution

The strongest legacy of Ghimire’s work will be measured by structures resolved, collaborations formed and students equipped to ask better questions of solid materials. His example gives Nepal’s chemistry community a clear connection between rigorous crystallography and public health: a molecule’s shape is not an abstract detail once that molecule becomes a medicine. That connection can be preserved in reusable teaching resources, extending the reach of one conversation or laboratory beyond the people present at the time.

The immediate action is to produce a companion multimedia teaching file, pairing Ghimire’s insights with one annotated diffraction dataset, a plain-language guide to an ORTEP plot and an open exercise for students in Nepal and Australia.